液体塞栓剤の市場規模、シェア、動向分析レポート：製品タイプ別、用途別、最終用途別、地域別、セグメント別予測、2025年～2033年

液体塞栓剤市場の概要

液体塞栓剤の世界市場規模は2024年に2億5,790万米ドルと推定され、2033年には5億9,500万米ドルに達すると予測され、2025～2033年のCAGRは9.89%で成長します。液体塞栓剤産業は、主に低侵襲手技の進歩と世界の血管疾患の有病率の増加によって牽引されています。

ヘルスケアシステムが低侵襲技術にシフトするにつれ、動脈瘤、動静脈奇形（AVM）、腫瘍といった疾患の治療に使用される塞栓剤の需要が急増しています。特に、AVM、硬膜動静脈瘻（DAVF）、多血管腫瘍などの神経血管や末梢血管の異常や疾患の増加が、主に市場成長の原動力となっています。National Center for BIoTechnology Informationが発表した調査紙製によると、動静脈奇形（AVM）は臨床的事象が発生するまで約15％の症例で無症状であることが多いです。AVMの41％から79％は頭蓋内出血を伴います。AVMは脳動脈瘤に次いで多い頭蓋内出血の原因であり、くも膜下出血の約10％を占めます。

小児は成人よりも出血を認める可能性が高いです。典型的な出血は脳実質内出血であるが、くも膜下腔で起こることもあります。また、Radiopaedia.orgが2024年11月に発表した紙製によると、孤立性AVMの発生率は98％、多発性AVMの発生率は2％です。したがって、AVM症例の増加は市場成長の主要因です。

さらに、2021年4月に発表された米国化学会の報告書によると、脳動脈瘤は主に脳血管の分岐点で発生する異常拡大です。現在、動脈瘤の60％以上は、流路迂回術や金属製嚢内コイルの永久留置といった低侵襲の血管内治療技術を用いて管理されています。しかし、これらの現在の器具は、約20～30％の症例で一次的成功率が芳しくなく、全体的な有効性は動脈瘤のタイプや部位によって大きく異なります。したがって、このことは予測期間中、液体塞栓剤産業に成長機会をもたらします。

神経血管塞栓術は、AVM、DAVF、多血管腫瘍などの疾患を治療するために液体塞栓剤を用いて行われるのが一般的です。現在、一般的に使用されている液体塞栓剤には、n-ブチルシアノアクリレート（n-BCA）やエチレンビニルアルコール共重合体（EVOH）ベース薬剤があり、オニキス（メドトロニック）、イカ（バルト）、非生分解性ヨードベース液体塞栓剤PHIL（テルモ）などがあります。さらに最近、TRUFILL（CERENOVUS、ジョンソン・エンド・ジョンソン）が登場しました。例えば、2024年3月、ジョンソン・エンド・ジョンソンMedTechの一部門であるCERENOVUSは、TRUFILL n-BCA液体塞栓システム手順セットの発売を発表しました。この新しい製品は、TRUFILL n-BCA液体塞栓システムの準備と投与に必要な2つの構成オプションとすべての付属品を含む包括的な手順セットを提供することにより、セレノバスの出血性脳卒中ポートフォリオを拡大するものです。これらの塞栓剤は、異常な血管構造を効果的に閉塞させ、高精度で低侵襲な治療を可能にすることから支持されています。塞栓剤の選択は、特定の臨床シナリオと病変の特徴に依存し、神経インターベンション治療における安全性、取り扱い、長期的な有効性の向上を目指した技術革新が進行中です。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 液体塞栓剤市場の変数、動向、範囲

• 市場系統の展望
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
  • 市場機会分析
  • 市場課題分析
• 液体塞栓剤市場分析ツール
  • 産業分析-ポーターのファイブフォース分析
  • PESTEL分析

第4章 液体塞栓剤市場：製品タイプ別、推定・動向分析

• セグメントダッシュボード
• 世界の液体塞栓剤市場の変動分析
• 世界の液体塞栓剤市場規模と動向分析（製品タイプ別、2021～2033年）
• エチレンビニルアルコール共重合体（EVOH）
• シアノアクリレート
• その他

第5章 液体塞栓剤市場：用途別、推定・動向分析

• セグメントダッシュボード
• 世界の液体塞栓剤市場の変動分析
• 世界の液体塞栓剤市場規模と動向分析（用途別、2021～2033年）
• 動静脈奇形（AVM）
• 多血性腫瘍
• 末梢血管出血
• その他

第6章 液体塞栓剤市場：最終用途別、推定・動向分析

• セグメントダッシュボード
• 世界の液体塞栓剤市場の変動分析
• 世界の液体塞栓剤市場規模と動向分析（最終用途別、2021～2033年）
• 病院
• 専門クリニック
• 外来手術センター（ASC）
• その他

第7章 液体塞栓剤市場：地域別、推定・動向分析（製品タイプ別、用途別、最終用途別）

• 地域ダッシュボード
• 市場規模と予測と動向分析、2021～2033年
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • デンマーク
  • スウェーデン
  • ノルウェー
• アジア太平洋
  • 日本
  • 中国
  • インド
  • 韓国
  • オーストラリア
  • タイ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第8章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 企業/競合の分類
  • イノベーター
• ベンダー情勢
  • 主要販売代理店とチャネルパートナー一覧
  • Global 主要企業の市場シェア分析、2024年
  • Johnson & Johnson
  • Medtronic
  • B. Braun SE
  • Terumo
  • Boston Scientific Corporation
  • Balt
  • BlackSwan Vascular, Inc.
  • INVAMED
  • Meril
  • Gem srl
• ヒートマップ分析/企業市況分析
• 2024年の企業市場シェア予測分析
• その他の主要市場参入企業一覧

List of Tables

• Table 1. List of Secondary Sources
• Table 2. List of Abbreviations
• Table 3. Global Liquid Embolic Agent Market, by Region, 2021 - 2033 (USD Million)
• Table 4. Global Liquid Embolic Agent Market, by Product Type, 2021 - 2033 (USD Million)
• Table 5. Global Liquid Embolic Agent Market, by Application, 2021 - 2033 (USD Million)
• Table 6. Global Liquid Embolic Agent Market, by End Use, 2021 - 2033 (USD Million)
• Table 7. North America Liquid Embolic Agent Market, by Country, 2021 - 2033 (USD Million)
• Table 8. North America Liquid Embolic Agent Market, by Product Type, 2021 - 2033 (USD Million)
• Table 9. North America Liquid Embolic Agent Market, by Application, 2021 - 2033 (USD Million)
• Table 10. North America Liquid Embolic Agent Market, by End Use, 2021 - 2033 (USD Million)
• Table 11. U.S. Liquid Embolic Agent Market, by Product Type, 2021 - 2033 (USD Million)
• Table 12. U.S. Liquid Embolic Agent Market, by Application, 2021 - 2033 (USD Million)
• Table 13. U.S. Liquid Embolic Agent Market, by End Use, 2021 - 2033 (USD Million)
• Table 14. Canada Liquid Embolic Agent Market, by Product Type, 2021 - 2033 (USD Million)
• Table 15. Canada Liquid Embolic Agent Market, by Application, 2021 - 2033 (USD Million)
• Table 16. Canada Liquid Embolic Agent Market, by End Use, 2021 - 2033 (USD Million)
• Table 17. Europe Liquid Embolic Agent Market, by Country, 2021 - 2033 (USD Million)
• Table 18. Europe Liquid Embolic Agent Market, by Product Type, 2021 - 2033 (USD Million)
• Table 19. Europe Liquid Embolic Agent Market, by Application, 2021 - 2033 (USD Million)
• Table 20. Europe Liquid Embolic Agent Market, by End Use, 2021 - 2033 (USD Million)
• Table 21. Germany Liquid Embolic Agent Market, by Product Type, 2021 - 2033 (USD Million)
• Table 22. Germany Liquid Embolic Agent Market, by Application, 2021 - 2033 (USD Million)
• Table 23. Germany Liquid Embolic Agent Market, by End Use, 2021 - 2033 (USD Million)
• Table 24. UK Liquid Embolic Agent Market, by Product Type, 2021 - 2033 (USD Million)
• Table 25. UK Liquid Embolic Agent Market, by Application, 2021 - 2033 (USD Million)
• Table 26. UK Liquid Embolic Agent Market, by End Use, 2021 - 2033 (USD Million)
• Table 27. France Liquid Embolic Agent Market, by Product Type, 2021 - 2033 (USD Million)
• Table 28. France Liquid Embolic Agent Market, by Application, 2021 - 2033 (USD Million)
• Table 29. France Liquid Embolic Agent Market, by End Use, 2021 - 2033 (USD Million)
• Table 30. Italy Liquid Embolic Agent Market, by Product Type, 2021 - 2033 (USD Million)
• Table 31. Italy Liquid Embolic Agent Market, by Application, 2021 - 2033 (USD Million)
• Table 32. Italy Liquid Embolic Agent Market, by End Use, 2021 - 2033 (USD Million)
• Table 33. Spain Liquid Embolic Agent Market, by Product Type, 2021 - 2033 (USD Million)
• Table 34. Spain Liquid Embolic Agent Market, by Application, 2021 - 2033 (USD Million)
• Table 35. Spain Liquid Embolic Agent Market, by End Use, 2021 - 2033 (USD Million)
• Table 36. Denmark Liquid Embolic Agent Market, by Product Type, 2021 - 2033 (USD Million)
• Table 37. Denmark Liquid Embolic Agent Market, by Application, 2021 - 2033 (USD Million)
• Table 38. Denmark Liquid Embolic Agent Market, by End Use, 2021 - 2033 (USD Million)
• Table 39. Sweden Liquid Embolic Agent Market, by Product Type, 2021 - 2033 (USD Million)
• Table 40. Sweden Liquid Embolic Agent Market, by Application, 2021 - 2033 (USD Million)
• Table 41. Sweden Liquid Embolic Agent Market, by End Use, 2021 - 2033 (USD Million)
• Table 42. Norway Liquid Embolic Agent Market, by Product Type, 2021 - 2033 (USD Million)
• Table 43. Norway Liquid Embolic Agent Market, by Application, 2021 - 2033 (USD Million)
• Table 44. Norway Liquid Embolic Agent Market, by End Use, 2021 - 2033 (USD Million)
• Table 45. Asia Pacific Liquid Embolic Agent Market, by Country, 2021 - 2033 (USD Million)
• Table 46. Asia Pacific Liquid Embolic Agent Market, by Product Type, 2021 - 2033 (USD Million)
• Table 47. Asia Pacific Liquid Embolic Agent Market, by Application, 2021 - 2033 (USD Million)
• Table 48. Asia Pacific Liquid Embolic Agent Market, by End Use, 2021 - 2033 (USD Million)
• Table 49. China Liquid Embolic Agent Market, by Product Type, 2021 - 2033 (USD Million)
• Table 50. China Liquid Embolic Agent Market, by Application, 2021 - 2033 (USD Million)
• Table 51. China Liquid Embolic Agent Market, by End Use, 2021 - 2033 (USD Million)
• Table 52. Japan Liquid Embolic Agent Market, by Product Type, 2021 - 2033 (USD Million)
• Table 53. Japan Liquid Embolic Agent Market, by Application, 2021 - 2033 (USD Million)
• Table 54. Japan Liquid Embolic Agent Market, by End Use, 2021 - 2033 (USD Million)
• Table 55. India Liquid Embolic Agent Market, by Product Type, 2021 - 2033 (USD Million)
• Table 56. India Liquid Embolic Agent Market, by Application, 2021 - 2033 (USD Million)
• Table 57. India Liquid Embolic Agent Market, by End Use, 2021 - 2033 (USD Million)
• Table 58. South Korea Liquid Embolic Agent Market, by Product Type, 2021 - 2033 (USD Million)
• Table 59. South Korea Liquid Embolic Agent Market, by Application, 2021 - 2033 (USD Million)
• Table 60. South Korea Liquid Embolic Agent Market, by End Use, 2021 - 2033 (USD Million)
• Table 61. Australia Liquid Embolic Agent Market, by Product Type, 2021 - 2033 (USD Million)
• Table 62. Australia Liquid Embolic Agent Market, by Application, 2021 - 2033 (USD Million)
• Table 63. Australia Liquid Embolic Agent Market, by End Use, 2021 - 2033 (USD Million)
• Table 64. Thailand Liquid Embolic Agent Market, by Product Type, 2021 - 2033 (USD Million)
• Table 65. Thailand Liquid Embolic Agent Market, by Application, 2021 - 2033 (USD Million)
• Table 66. Thailand Liquid Embolic Agent Market, by End Use, 2021 - 2033 (USD Million)
• Table 67. Latin America Liquid Embolic Agent Market, by Country, 2021 - 2033 (USD Million)
• Table 68. Latin America Liquid Embolic Agent Market, by Product Type, 2021 - 2033 (USD Million)
• Table 69. Latin America Liquid Embolic Agent Market, by Application, 2021 - 2033 (USD Million)
• Table 70. Latin America Liquid Embolic Agent Market, by End Use, 2021 - 2033 (USD Million)
• Table 71. Brazil Liquid Embolic Agent Market, by Product Type, 2021 - 2033 (USD Million)
• Table 72. Brazil Liquid Embolic Agent Market, by Application, 2021 - 2033 (USD Million)
• Table 73. Brazil Liquid Embolic Agent Market, by End Use, 2021 - 2033 (USD Million)
• Table 74. Mexico Liquid Embolic Agent Market, by Product Type, 2021 - 2033 (USD Million)
• Table 75. Mexico Liquid Embolic Agent Market, by Application, 2021 - 2033 (USD Million)
• Table 76. Mexico Liquid Embolic Agent Market, by End Use, 2021 - 2033 (USD Million)
• Table 77. Argentina Liquid Embolic Agent Market, by Product Type, 2021 - 2033 (USD Million)
• Table 78. Argentina Liquid Embolic Agent Market, by Application, 2021 - 2033 (USD Million)
• Table 79. Argentina Liquid Embolic Agent Market, by End Use, 2021 - 2033 (USD Million)
• Table 80. Middle East & Africa Liquid Embolic Agent Market, by Country, 2021 - 2033 (USD Million)
• Table 81. Middle East & Africa Liquid Embolic Agent Market, by Product Type, 2021 - 2033 (USD Million)
• Table 82. Middle East & Africa Liquid Embolic Agent Market, by Application, 2021 - 2033 (USD Million)
• Table 83. Middle East & Africa Liquid Embolic Agent Market, by End Use, 2021 - 2033 (USD Million)
• Table 84. South Africa Liquid Embolic Agent Market, by Product Type, 2021 - 2033 (USD Million)
• Table 85. South Africa Liquid Embolic Agent Market, by Application, 2021 - 2033 (USD Million)
• Table 86. South Africa Liquid Embolic Agent Market, by End Use, 2021 - 2033 (USD Million)
• Table 87. Saudi Arabia Liquid Embolic Agent Market, by Product Type, 2021 - 2033 (USD Million)
• Table 88. Saudi Arabia Liquid Embolic Agent Market, by Application, 2021 - 2033 (USD Million)
• Table 89. Saudi Arabia Liquid Embolic Agent Market, by End Use, 2021 - 2033 (USD Million)
• Table 90. UAE Liquid Embolic Agent Market, by Product Type, 2021 - 2033 (USD Million)
• Table 91. UAE Liquid Embolic Agent Market, by Application, 2021 - 2033 (USD Million)
• Table 92. UAE Liquid Embolic Agent Market, by End Use, 2021 - 2033 (USD Million)
• Table 93. Kuwait Liquid Embolic Agent Market, by Product Type, 2021 - 2033 (USD Million)
• Table 94. Kuwait Liquid Embolic Agent Market, by Application, 2021 - 2033 (USD Million)
• Table 95. Kuwait Liquid Embolic Agent Market, by End Use, 2021 - 2033 (USD Million)
• Table 96. Participant's Overview
• Table 97. Financial Performance
• Table 98. Product Benchmarking
• Table 99. Strategic Initiatives

List of Figures

• Fig. 1 Information Procurement
• Fig. 2 Primary Research Pattern
• Fig. 3 Market Research Approaches
• Fig. 4 Value Chain-Based Sizing & Forecasting
• Fig. 5 Market Formulation & Validation
• Fig. 6 Liquid Embolic Agent Market, Market Segmentation
• Fig. 7 Market Driver Analysis (Current & Future Impact)
• Fig. 8 Market Restraint Analysis (Current & Future Impact)
• Fig. 9 Market Opportunity Analysis (Current & Future Impact)
• Fig. 10 Market Challenge Analysis (Current & Future Impact)
• Fig. 11 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
• Fig. 12 Porter's Five Forces Analysis
• Fig. 13 Regional Marketplace: Key Takeaways
• Fig. 14 Global Liquid Embolic Agent Market, for Ethylene Vinyl Alcohol Copolymer (EVOH), 2021 - 2033 (USD Million)
• Fig. 15 Global Liquid Embolic Agent Market, for Cyanoacrylates, 2021 - 2033 (USD Million)
• Fig. 16 Global Liquid Embolic Agent Market, for N-BCA (n-Butyl Cyanoacrylate), 2021 - 2033 (USD Million)
• Fig. 17 Global Liquid Embolic Agent Market, for N-HCA (n-Hexyl Cyanoacrylate), 2021 - 2033 (USD Million)
• Fig. 18 Global Liquid Embolic Agent Market, for Others, 2021 - 2033 (USD Million)
• Fig. 19 Global Liquid Embolic Agent Market, for Arteriovenous Malformations (AVM), 2021 - 2033 (USD Million)
• Fig. 20 Global Liquid Embolic Agent Market, for Hypervascular Tumors, 2021 - 2033 (USD Million)
• Fig. 21 Global Liquid Embolic Agent Market, for Peripheral Vasculature Hemorrhage, 2021 - 2033 (USD Million)
• Fig. 22 Global Liquid Embolic Agent Market, for Others, 2021 - 2033 (USD Million)
• Fig. 23 Global Liquid Embolic Agent Market, for Hospitals, 2021 - 2033 (USD Million)
• Fig. 24 Global Liquid Embolic Agent Market, for Specialty Clinics, 2021 - 2033 (USD Million)
• Fig. 25 Global Liquid Embolic Agent Market, for Ambulatory Surgical Centers (ASCs), 2021 - 2033 (USD Million)
• Fig. 26 Global Liquid Embolic Agent Market, for Others, 2021 - 2033 (USD Million)
• Fig. 27 Regional Outlook, 2024 & 2033
• Fig. 28 North America Liquid Embolic Agent Market, 2021 - 2033 (USD Million)
• Fig. 29 U.S. Liquid Embolic Agent Market, 2021 - 2033 (USD Million)
• Fig. 30 Canada Liquid Embolic Agent Market, 2021 - 2033 (USD Million)
• Fig. 31 Europe Liquid Embolic Agent Market, 2021 - 2033 (USD Million)
• Fig. 32 Germany Liquid Embolic Agent Market, 2021 - 2033 (USD Million)
• Fig. 33 UK Liquid Embolic Agent Market, 2021 - 2033 (USD Million)
• Fig. 34 France Liquid Embolic Agent Market, 2021 - 2033 (USD Million)
• Fig. 35 Italy Liquid Embolic Agent Market, 2021 - 2033 (USD Million)
• Fig. 36 Spain Liquid Embolic Agent Market, 2021 - 2033 (USD Million)
• Fig. 37 Denmark Liquid Embolic Agent Market, 2021 - 2033 (USD Million)
• Fig. 38 Sweden Liquid Embolic Agent Market, 2021 - 2033 (USD Million)
• Fig. 39 Norway Liquid Embolic Agent Market, 2021 - 2033 (USD Million)
• Fig. 40 Asia Pacific Liquid Embolic Agent Market, 2021 - 2033 (USD Million)
• Fig. 41 Japan Liquid Embolic Agent Market, 2021 - 2033 (USD Million)
• Fig. 42 China Liquid Embolic Agent Market, 2021 - 2033 (USD Million)
• Fig. 43 India Liquid Embolic Agent Market, 2021 - 2033 (USD Million)
• Fig. 44 Australia Liquid Embolic Agent Market, 2021 - 2033 (USD Million)
• Fig. 45 South Korea Liquid Embolic Agent Market, 2021 - 2033 (USD Million)
• Fig. 46 Thailand Liquid Embolic Agent Market, 2021 - 2033 (USD Million)
• Fig. 47 Latin America Liquid Embolic Agent Market, 2021 - 2033 (USD Million)
• Fig. 48 Brazil Liquid Embolic Agent Market, 2021 - 2033 (USD Million)
• Fig. 49 Mexico Liquid Embolic Agent Market, 2021 - 2033 (USD Million)
• Fig. 50 Argentina Liquid Embolic Agent Market, 2021 - 2033 (USD Million)
• Fig. 51 Middle East and Africa Liquid Embolic Agent Market, 2021 - 2033 (USD Million)
• Fig. 52 South Africa Liquid Embolic Agent Market, 2021 - 2033 (USD Million)
• Fig. 53 Saudi Arabia Liquid Embolic Agent Market, 2021 - 2033 (USD Million)
• Fig. 54 UAE Liquid Embolic Agent Market, 2021 - 2033 (USD Million)
• Fig. 55 Kuwait Liquid Embolic Agent Market, 2021 - 2033 (USD Million)

Liquid Embolic Agent Market Summary

The global liquid embolic agent market size was estimated at USD 257.9 million in 2024 and is projected to reach USD 595.0 million by 2033, growing at a CAGR of 9.89% from 2025 to 2033. The liquid embolic agent industry is primarily driven by advancements in minimally invasive procedures and the increasing prevalence of vascular diseases worldwide.

As healthcare systems shift towards less invasive techniques, the demand for embolization agents used in treating conditions like aneurysms, arteriovenous malformations (AVMs), and tumors has surged. The growing neurovascular and peripheral vascular abnormalities and diseases such as AVMs, dural arteriovenous fistulas (DAVFs), and hypervascular tumors, among others are primarily driving the market growth. According to a research article published by the National Center for Biotechnology Information, arteriovenous malformations (AVMs) are often asymptomatic in about 15% of cases until a clinical event occurs. Between 41% and 79% of AVMs are present with intracranial hemorrhage. They are the second most common cause of intracranial bleeding after cerebral aneurysms, accounting for approximately 10% of all subarachnoid hemorrhages.

Children are more likely than adults to be present with hemorrhage. While hemorrhages are typically intraparenchymal, they can also primarily occur in the subarachnoid space. In addition, according to an article published by Radiopaedia.org in November 2024, the incidence of solitary AVM is 98% and multiple AVM is 2%. Thus, growing AVM cases are a primary contributor to market growth.

Furthermore, according to an American Chemical Society report published in April 2021, brain aneurysms are abnormal dilations that primarily develop at the branch points of cerebral blood vessels. Over 60% of aneurysms are now managed using minimally invasive endovascular techniques, such as flow diversion or the permanent placement of metallic intrasaccular coils. However, these current devices have an unfavorable primary success rate in approximately 20-30% of cases, and the overall effectiveness varies significantly depending on the aneurysm's type and location. Hence, this brings a growth opportunity for the liquid embolic agent industry during the forecast period.

Neurovascular embolization is commonly performed using liquid embolic agents to treat conditions such as AVMs, DAVFs, and hypervascular tumors. Currently, commonly used liquid embolic agents include n-butyl cyanoacrylate (n-BCA) and ethylene vinyl alcohol copolymer (EVOH) based agents, such as Onyx (Medtronic), Squid (Balt), and PHIL (Terumo), a non-biodegradable iodine-based liquid embolic agent. Additionally, TRUFILL (CERENOVUS, Johnson & Johnson) has recently been introduced. For instance, in March 2024, CERENOVUS, a division of Johnson & Johnson MedTech, announced the launch of the TRUFILL n-BCA Liquid Embolic System Procedural Set. This new offer expands CERENOVUS's hemorrhagic stroke portfolio by providing a comprehensive procedural set that includes two configuration options and all necessary accessories for preparing and delivering the TRUFILL n-BCA Liquid Embolic System. These agents are favored for their ability to effectively occlude abnormal vascular structures, providing minimally invasive treatment options with high precision. The choice of embolic agent depends on the specific clinical scenario and lesion characteristics, with ongoing innovations aiming to improve safety, handling, and long-term efficacy in neurointerventional procedures.

Global Liquid Embolic Agent Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis on the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global liquid embolic agent market report based on product type, application, end use, and region:

• Product Type Outlook (Revenue, USD Million, 2021 - 2033)
• Ethylene Vinyl Alcohol Copolymer (EVOH)
• Cyanoacrylates
  • N-BCA (n-Butyl Cyanoacrylate)
  • N-HCA (n-Hexyl Cyanoacrylate)
• Others
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Arteriovenous Malformations (AVM)
• Hypervascular Tumors
• Peripheral Vasculature Hemorrhage
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers (ASCs)
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Product Type
  • 1.1.2. Application
  • 1.1.3. End-use
  • 1.1.4. Regional scope
  • 1.1.5. Estimates and forecast timeline
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity flow analysis (Model 1)
    • 1.6.1.1. Approach 1: Commodity flow approach
  • 1.6.2. Volume price analysis (Model 2)
    • 1.6.2.1. Approach 2: Volume price analysis
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives
  • 1.9.1. Objective 1
  • 1.9.2. Objective 2

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Liquid Embolic Agent Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Rising Prevalence of Vascular Diseases
    • 3.2.1.2. Advancements in Embolization Technologies
    • 3.2.1.3. Growing Preference for Minimally Invasive Procedures
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High cost of agents and materials
    • 3.2.2.2. Risk of complications and adverse events
    • 3.2.2.3. Availability of alternative treatments
  • 3.2.3. Market Opportunities Analysis
    • 3.2.3.1. Technological innovations
    • 3.2.3.2. Growing number of clinical trials
    • 3.2.3.3. Expanding application areas
  • 3.2.4. Market Challenge Analysis
    • 3.2.4.1. Regulatory and approval barriers
• 3.3. Liquid Embolic Agent Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political & Legal Landscape
    • 3.3.2.2. Economic and Social Landscape
    • 3.3.2.3. Technological landscape

Chapter 4. Liquid Embolic Agent Market: Product Type Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Liquid Embolic Agent Market Movement Analysis
• 4.3. Global Liquid Embolic Agent Market Size & Trend Analysis, by Product Type, 2021 to 2033 (USD Million)
• 4.4. Ethylene Vinyl Alcohol Copolymer (EVOH)
  • 4.4.1. Ethylene Vinyl Alcohol Copolymer (EVOH) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Cyanoacrylates
  • 4.5.1. Cyanoacrylates Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.1.1. N-BCA (n-Butyl Cyanoacrylate)
      • 4.5.1.1.1. N-BCA (n-Butyl Cyanoacrylate) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.5.1.2. N-HCA (n-Hexyl Cyanoacrylate)
      • 4.5.1.2.1. N-HCA (n-Hexyl Cyanoacrylate) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Others
  • 4.6.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Liquid Embolic Agent Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Liquid Embolic Agent Market Movement Analysis
• 5.3. Global Liquid Embolic Agent Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
• 5.4. Arteriovenous Malformations (AVM)
  • 5.4.1. Arteriovenous Malformations (AVM) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Hypervascular Tumors
  • 5.5.1. Hypervascular Tumors Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Peripheral Vasculature Hemorrhage
  • 5.6.1. Peripheral Vasculature Hemorrhage Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.7. Others
  • 5.7.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Liquid Embolic Agent Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Liquid Embolic Agent Market Movement Analysis
• 6.3. Global Liquid Embolic Agent Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
• 6.4. Hospitals
  • 6.4.1. Hospitals Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Specialty Clinics
  • 6.5.1. Specialty Clinics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Ambulatory Surgical Centers (ASCs)
  • 6.6.1. Ambulatory Surgical Centers (ASCs) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.7. Others
  • 6.7.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Liquid Embolic Agent Market: Regional Estimates & Trend Analysis By Product Type, By Application, By End Use

• 7.1. Regional Dashboard
• 7.2. Market Size & Forecasts and Trend Analysis, 2021 to 2033
• 7.3. North America
  • 7.3.1. North America Liquid Embolic Agent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.2. U.S.
    • 7.3.2.1. Key Country Dynamics
    • 7.3.2.2. Competitive Scenario
    • 7.3.2.3. Regulatory Scenario
    • 7.3.2.4. Reimbursement Scenario
    • 7.3.2.5. U.S. Liquid Embolic Agent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.3. Canada
    • 7.3.3.1. Key Country Dynamics
    • 7.3.3.2. Competitive Scenario
    • 7.3.3.3. Regulatory Scenario
    • 7.3.3.4. Reimbursement Scenario
    • 7.3.3.5. Canada Liquid Embolic Agent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.4. Mexico
    • 7.3.4.1. Key Country Dynamics
    • 7.3.4.2. Competitive Scenario
    • 7.3.4.3. Regulatory Scenario
    • 7.3.4.4. Reimbursement Scenario
    • 7.3.4.5. Mexico Liquid Embolic Agent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.4. Europe
  • 7.4.1. Europe Liquid Embolic Agent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.2. UK
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Competitive Scenario
    • 7.4.2.3. Regulatory Scenario
    • 7.4.2.4. Reimbursement Scenario
    • 7.4.2.5. UK Liquid Embolic Agent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.3. Germany
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Competitive Scenario
    • 7.4.3.3. Regulatory Scenario
    • 7.4.3.4. Reimbursement Scenario
    • 7.4.3.5. Germany Liquid Embolic Agent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.4. France
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Competitive Scenario
    • 7.4.4.3. Regulatory Scenario
    • 7.4.4.4. Reimbursement Scenario
    • 7.4.4.5. France Liquid Embolic Agent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.5. Italy
    • 7.4.5.1. Key Country Dynamics
    • 7.4.5.2. Competitive Scenario
    • 7.4.5.3. Regulatory Scenario
    • 7.4.5.4. Reimbursement Scenario
    • 7.4.5.5. Italy Liquid Embolic Agent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.6. Spain
    • 7.4.6.1. Key Country Dynamics
    • 7.4.6.2. Competitive Scenario
    • 7.4.6.3. Regulatory Scenario
    • 7.4.6.4. Reimbursement Scenario
    • 7.4.6.5. Spain Liquid Embolic Agent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.7. Denmark
    • 7.4.7.1. Key Country Dynamics
    • 7.4.7.2. Competitive Scenario
    • 7.4.7.3. Regulatory Scenario
    • 7.4.7.4. Reimbursement Scenario
    • 7.4.7.5. Denmark Liquid Embolic Agent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.8. Sweden
    • 7.4.8.1. Key Country Dynamics
    • 7.4.8.2. Competitive Scenario
    • 7.4.8.3. Regulatory Scenario
    • 7.4.8.4. Reimbursement Scenario
    • 7.4.8.5. Sweden Liquid Embolic Agent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.9. Norway
    • 7.4.9.1. Key Country Dynamics
    • 7.4.9.2. Competitive Scenario
    • 7.4.9.3. Regulatory Scenario
    • 7.4.9.4. Reimbursement Scenario
    • 7.4.9.5. Norway Liquid Embolic Agent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Asia Pacific Liquid Embolic Agent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.2. Japan
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Competitive Scenario
    • 7.5.2.3. Regulatory Scenario
    • 7.5.2.4. Reimbursement Scenario
    • 7.5.2.5. Japan Liquid Embolic Agent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.3. China
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Competitive Scenario
    • 7.5.3.3. Regulatory Scenario
    • 7.5.3.4. Reimbursement Scenario
    • 7.5.3.5. China Liquid Embolic Agent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.4. India
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Competitive Scenario
    • 7.5.4.3. Regulatory Scenario
    • 7.5.4.4. Reimbursement Scenario
    • 7.5.4.5. India Liquid Embolic Agent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.5. South Korea
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Competitive Scenario
    • 7.5.5.3. Regulatory Scenario
    • 7.5.5.4. Reimbursement Scenario
    • 7.5.5.5. South Korea Liquid Embolic Agent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.6. Australia
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Competitive Scenario
    • 7.5.6.3. Regulatory Scenario
    • 7.5.6.4. Reimbursement Scenario
    • 7.5.6.5. Australia Liquid Embolic Agent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.7. Thailand
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Competitive Scenario
    • 7.5.7.3. Regulatory Scenario
    • 7.5.7.4. Reimbursement Scenario
    • 7.5.7.5. Thailand Liquid Embolic Agent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Latin America
  • 7.6.1. Latin America Liquid Embolic Agent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.2. Brazil
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Competitive Scenario
    • 7.6.2.3. Regulatory Scenario
    • 7.6.2.4. Reimbursement Scenario
    • 7.6.2.5. Brazil Liquid Embolic Agent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.3. Argentina
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Competitive Scenario
    • 7.6.3.3. Regulatory Scenario
    • 7.6.3.4. Reimbursement Scenario
    • 7.6.3.5. Argentina Liquid Embolic Agent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.7. Middle East & Africa
  • 7.7.1. Middle East & Africa Liquid Embolic Agent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.2. South Africa
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Competitive Scenario
    • 7.7.2.3. Regulatory Scenario
    • 7.7.2.4. Reimbursement Scenario
    • 7.7.2.5. South Africa Liquid Embolic Agent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.3. Saudi Arabia
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Competitive Scenario
    • 7.7.3.3. Regulatory Scenario
    • 7.7.3.4. Reimbursement Scenario
    • 7.7.3.5. Saudi Arabia Liquid Embolic Agent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.4. UAE
    • 7.7.4.1. Key Country Dynamics
    • 7.7.4.2. Competitive Scenario
    • 7.7.4.3. Regulatory Scenario
    • 7.7.4.4. Reimbursement Scenario
    • 7.7.4.5. UAE Liquid Embolic Agent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.5. Kuwait
    • 7.7.5.1. Key Country Dynamics
    • 7.7.5.2. Competitive Scenario
    • 7.7.5.3. Regulatory Scenario
    • 7.7.5.4. Reimbursement Scenario
    • 7.7.5.5. Kuwait Liquid Embolic Agent Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
  • 8.2.1. Innovators
• 8.3. Vendor Landscape
  • 8.3.1. List of key distributors and channel partners
  • 8.3.2. Key customers
  • 8.3.3. Global Key company market share analysis, 2024
  • 8.3.4. Johnson & Johnson
    • 8.3.4.1. Company Overview
    • 8.3.4.2. Financial Performance
    • 8.3.4.3. Service Benchmarking
    • 8.3.4.4. Strategic Initiatives
  • 8.3.5. Medtronic
    • 8.3.5.1. Company Overview
    • 8.3.5.2. Financial Performance
    • 8.3.5.3. Service Benchmarking
    • 8.3.5.4. Strategic Initiatives
  • 8.3.6. B. Braun SE
    • 8.3.6.1. Company Overview
    • 8.3.6.2. Financial Performance
    • 8.3.6.3. Product Benchmarking
    • 8.3.6.4. Strategic Initiatives
  • 8.3.7. Terumo
    • 8.3.7.1. Company Overview
    • 8.3.7.2. Financial Performance
    • 8.3.7.3. Product Benchmarking
    • 8.3.7.4. Strategic Initiatives
  • 8.3.8. Boston Scientific Corporation
    • 8.3.8.1. Company Overview
    • 8.3.8.2. Financial Performance
    • 8.3.8.3. Product Benchmarking
    • 8.3.8.4. Strategic Initiatives
  • 8.3.9. Balt
    • 8.3.9.1. Company Overview
    • 8.3.9.2. Financial Performance
    • 8.3.9.3. Product Benchmarking
    • 8.3.9.4. Strategic Initiatives
  • 8.3.10. BlackSwan Vascular, Inc.
    • 8.3.10.1. Company Overview
    • 8.3.10.2. Financial Performance
    • 8.3.10.3. Product Benchmarking
    • 8.3.10.4. Strategic Initiatives
  • 8.3.11. INVAMED
    • 8.3.11.1. Company Overview
    • 8.3.11.2. Financial Performance
    • 8.3.11.3. Product Benchmarking
    • 8.3.11.4. Strategic Initiatives
  • 8.3.12. Meril
    • 8.3.12.1. Company Overview
    • 8.3.12.2. Financial Performance
    • 8.3.12.3. Product Benchmarking
    • 8.3.12.4. Strategic Initiatives
  • 8.3.13. Gem srl
    • 8.3.13.1. Company Overview
    • 8.3.13.2. Financial Performance
    • 8.3.13.3. Product Benchmarking
    • 8.3.13.4. Strategic Initiatives
• 8.4. Heat Map Analysis/ Company Market Position Analysis
• 8.5. Estimated Company Market Share Analysis, 2024
• 8.6. List of Other Key Market Players